Department of Pharmacology, Key Laboratory of Drug‑Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant‑Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.
Int J Oncol. 2022 Sep;61(3). doi: 10.3892/ijo.2022.5391. Epub 2022 Jul 7.
Gliomas are a primary types of intracranial malignancies and are characterized by a poor prognosis due to aggressive recurrence profiles. Temozolomide (TMZ) is an auxiliary alkylating agent that is extensively used in conjunction with surgical resection and forms the mainstay of clinical treatment strategies for gliomas. However, the frequent occurrence of TMZ resistance in clinical practice limits its therapeutic efficacy. Accumulating evidence has demonstrated that long non‑coding RNAs (lncRNAs) can play key and varied roles in glioma progression. lncRNAs have been reported to inhibit glioma progression by targeting various signaling pathways. In addition, the differential expression of lncRNAs has also been found to mediate the resistance of glioma to several chemotherapeutic agents, particularly to TMZ. The present review article therefore summarizes the findings of previous studies in an aim to report the significance and function of lncRNAs in regulating the chemoresistance of gliomas. The present review may provide further insight into the clinical treatment of gliomas.
神经胶质瘤是颅内原发性恶性肿瘤的一种，其侵袭性的复发特征导致预后较差。替莫唑胺（TMZ）是一种辅助烷化剂，广泛应用于与手术切除联合，并构成神经胶质瘤临床治疗策略的主要支柱。然而，TMZ 耐药在临床实践中频繁发生，限制了其治疗效果。越来越多的证据表明，长链非编码 RNA（lncRNA）在神经胶质瘤进展中可发挥关键且多样化的作用。有报道称，lncRNA 通过靶向各种信号通路来抑制神经胶质瘤的进展。此外，lncRNA 的差异表达也被发现介导了神经胶质瘤对多种化疗药物，特别是 TMZ 的耐药性。因此，本综述文章总结了之前研究的结果，旨在报告 lncRNA 在调节神经胶质瘤化疗耐药性方面的意义和功能。本综述可能为神经胶质瘤的临床治疗提供进一步的见解。
